Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Go back to Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer| Pfizer Inc. (NYSE: PFE) | Delayed: 24.01 -0.03 (0.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.04 | 52 Week High | $37.39 | |||
| Open | $24.19 | 52 Week Low | $28.25 | |||
| Day High | $24.34 | P/E | 14.55 | |||
| Day Low | $23.99 | EPS | $1.65 | |||
| Volume | 19,323,347 | |||||
